Oral Semaglutide Shows Promise for Rare Genetic Diabetes (HNF4A-MODY)

Maturity-Onset Diabetes of the Young (MODY) is a group of monogenic diabetes forms, distinct from type 1 and type 2 diabetes. Hepatocyte Nuclear Factor 4A (HNF4A) MODY is a specific subtype often characterized by early-onset, progressive beta-cell dysfunction and sensitivity to sulfonylureas. Current treatments, while effective, can lead to challenges like hypoglycemia or weight gain, and there's a need for alternative therapies. This case study addresses the potential utility of oral semaglutide, a GLP-1 receptor agonist, in managing HNF4A-MODY.

After 6 months of treatment with oral semaglutide, the patient demonstrated a significant improvement in glycemic control. Her HbA1c decreased from an initial 8.5% to 6.2%, representing an absolute reduction of 2.3%. Fasting blood glucose levels also saw a substantial decrease, falling from an average of 180 mg/dL to 105 mg/dL, a 41.7% reduction. The patient experienced a weight loss of 7.5 kg (10% of her initial body weight) and reported only mild, transient gastrointestinal side effects. >The patient was successfully able to discontinue glipizide entirely and reduce her metformin dosage by 50%, indicating a profound improvement in glycemic management and a reduction in polypharmacy. This suggests oral semaglutide effectively enhanced insulin secretion and sensitivity in this specific MODY patient.